Abstract

Tumor Microenvironment heterogeneity plays a key role in drug delivery, metabolism, response and resistance. Mass Spectrometry Imaging (MSI) techniques can provide unmatched information about regional tumor metabolic profile and detection of greater heterogeneity in tumour response than visible by traditional pathology methods such as H&E. Relating this to specific biomarker information from Imaging Mass Cytometry (IMC) enables identification of the cell types, phenotypes and signaling networks underlying tumor heterogeneity. Innovative, information-rich technologies such as IMC and MSI is driving greater understanding of the impact of tumour heterogeneity on drug efficacy in vivo and in patients